1
|
Puthenparampil M, Marin A, Zanotelli G, Mauceri VA, De Napoli F, Gaggiola M, Miscioscia A, Ponzano M, Bovis F, Perini P, Rinaldi F, Molon B, Gallo P. Blood-brain barrier damage associates with glia-related cytokines in the cerebrospinal fluid of patients with Multiple Sclerosis. Mult Scler Relat Disord 2024; 82:105403. [PMID: 38184910 DOI: 10.1016/j.msard.2023.105403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Accepted: 12/21/2023] [Indexed: 01/09/2024]
Abstract
BACKGROUND The presence of Blood-Brain Barrier (BBB) dysfunction is defined by albumin quotient (QALB) and characterize a group of Multiple Sclerosis (MS) patients at clinical onset. We evaluated the concentration in cerebrospinal fluid (CSF) of 87 cytokines, to better characterize the CSF inflammatory pattern in presence of BBB damage. MATERIALS AND METHOD In an exploratory cohort, CSF cytokines were evaluated by means of Multiplex technology (Bio-Plex Pro-Human Cytokine, GF and Diabetes 27-Plex Panel, Bio-Plex Pro-Human Chemokines 40-Plex Panel, Bio-Plex Pro-Human Inflammation Assays 37-Plex Panel) in a cohort of Other Not Inflammatory Neurological Disorders (ONIND) and in cohort of patients with MS, stratified according to BBB damage into QALB+ and QALB- MS patients. In the validation cohort, we evaluated the relevant molecules in a cohort of MS patients, stratified again into QALB+ and QALB-, including also Neurofilament Light (NfL) and Chitinase 3-like 1 (CHI3L1) CSF concentration. RESULTS While MIP-1α, CXCL-13, and CCL-22 CSF concentrations were higher in both MS groups compared to ONIND, in QALB+ MS CSF concentrations of CXCL-9 (17.85 ± 4.69 pg/mL), CXCL-10 (476.5 ± 324.3 pg/mL), and IL-16 (96.08 ± 86.17 pg/mL) were higher than in QALB- MS (8.98 ± 5368 pg/mL, p < 0.005, 281.0 ± 180.9 pg/mL, p < 0.05, and 47.35 ± 36.87 pg/mL, p < 0.005, respectively) and ONIND (8.98 ± 5368 pg/mlL, p < 0.005, 281.0 ± 180.9 pg/mL, p < 0.005, and 47.35 ± 36.87 pg/mL, p < 0.001, respectively). A strong correlation was observed between CXCL-9 and CXCL-10 in all MS groups (all r>0.75, all p < 0.001). In the validation cohort again CXCL-10 CSF concentration were higher in QALB+ MS than in QALB- MS (94.25 ± 64.75 vs 153.8 ± 99.52, p < 0.05), while no difference was observed in serum. CSF NfL (1642 ± 1963 vs 3231 ± 3492 pg/mL, p < 0.05) and CHI3L1 (183.9 ± 86.62 vs 262 ± 137.5 ng/mL, p < 0.05) were increased in QALB+ MS. CONCLUSIONS BBB damage in MS is linked to a specific CSF cytokines pattern (CXCL-9, CXCL-10, IL-16), that are also involved in astrocyte-microglia interaction. To what extent their continuous production in the CNS may mark a more severe disease course merits to be investigated.
Collapse
Affiliation(s)
- M Puthenparampil
- Department of Neurosciences, University of Padua, Padua, Italy; Multiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy.
| | - A Marin
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - G Zanotelli
- Department of Neurosciences, University of Padua, Padua, Italy; Multiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy
| | - V A Mauceri
- Department of Neurosciences, University of Padua, Padua, Italy; Multiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy
| | - F De Napoli
- Department of Neurosciences, University of Padua, Padua, Italy; Multiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy
| | - M Gaggiola
- Department of Neurosciences, University of Padua, Padua, Italy; Multiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy
| | - A Miscioscia
- Department of Neurosciences, University of Padua, Padua, Italy
| | - M Ponzano
- Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy
| | - F Bovis
- Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy
| | - P Perini
- Department of Neurosciences, University of Padua, Padua, Italy; Multiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy
| | - F Rinaldi
- Department of Neurosciences, University of Padua, Padua, Italy; Multiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy
| | - B Molon
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - P Gallo
- Department of Neurosciences, University of Padua, Padua, Italy; Multiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy
| |
Collapse
|
2
|
Nucera B, Rinaldi F, Dono F, Lanzone J, Evangelista G, Consoli S, Tappatà M, Narducci F, Troisi S, Trinka E, Brigo F. Progesterone and its derivatives for the treatment of catamenial epilepsy: A systematic review. Seizure 2023; 109:52-59. [PMID: 37229848 DOI: 10.1016/j.seizure.2023.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 05/02/2023] [Accepted: 05/04/2023] [Indexed: 05/27/2023] Open
Abstract
OBJECTIVE Catamenial epilepsy (CE) is defined as an increase in seizure frequency during specific phases of the menstrual cycle in women with epilepsy. The treatment usually includes a combination of non-hormonal and hormonal therapies. This systematic review summarizes the available data on the efficacy of progesterone and its derivates to treat CE. METHODS We performed a systematic search of the literature to identify studies reporting data on the use of progesterone and its derivatives (any type and dose) for the treatment of CE. The main outcome included the efficacy of progesterone and its derivatives on seizure frequency. RESULTS Nineteen articles (457 patients) were included; four were randomized controlled trials (two comparing progesterone vs placebo and two comparing norethisterone vs placebo). Progesterone was generally administered during the luteal phase (from day 15 to 25) or during perimenstrual exacerbations (from day 23 to 25), with an average dose of 10-30 mg/day to a maximum of 300 mg/day. The therapy, usually well tolerated, was ineffective in the randomized controlled trials; conversely, it was associated with an overall reduction in seizure frequency in case reports and uncontrolled studies. CONCLUSIONS Although data from uncontrolled studies suggest that hormone therapy with progesterone may be useful in the treatment of CE, its efficacy has not been demonstrated in controlled trials. The possible antiseizure effect of progesterone could be mediated by its active metabolite allopregnanolone, making the plasmatic measurement of these hormones mandatory to evaluate efficacy. Further randomized controlled trials should investigate the efficacy of progesterone and its derivatives, addressing these pharmacological issues.
Collapse
Affiliation(s)
- B Nucera
- Department of Neurology, Hospital of Merano (SABES-ASDAA), Merano, Italy; Paracelsus Medical University, A-5020 Salzburg, Austria.
| | - F Rinaldi
- Department of Neurology, Hospital of Merano (SABES-ASDAA), Merano, Italy; Paracelsus Medical University, A-5020 Salzburg, Austria
| | - F Dono
- Department of Neuroscience, Imaging and Clinical Science, ''G. D'Annunzio" University of Chieti-Pescara, Chieti, Italy
| | - J Lanzone
- Istituti Clinici Scientifici Maugeri IRCCS, Neurorehabilitation Unit of Milan Institute, Italy
| | - G Evangelista
- Department of Neuroscience, Imaging and Clinical Science, ''G. D'Annunzio" University of Chieti-Pescara, Chieti, Italy
| | - S Consoli
- Department of Neuroscience, Imaging and Clinical Science, ''G. D'Annunzio" University of Chieti-Pescara, Chieti, Italy
| | - M Tappatà
- IRCCS Istituto delle Scienze Neurolgiche di Bologna, Ospedale Bellaria, Italy
| | - F Narducci
- Unit of Neurology, Neurophysiology, Neurobiology, Department of Medicine, University Campus Bio-Medico of Rome, Italy
| | - S Troisi
- Pediatric Neurology, Department of Neuroscience, Santobono-Pausilipon Children's Hospital, Naples, Italy
| | - E Trinka
- Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University and Centre for Cognitive Neuroscience, Member of the ERN EpiCARE, Salzburg, Austria
| | - F Brigo
- Department of Neurology, Hospital of Merano (SABES-ASDAA), Merano, Italy
| |
Collapse
|
3
|
Fehrholz M, Piccini I, Timperi L, Mardaryev A, Pinto D, Rinaldi F, Paus R, Bíró T, Bertolini M. 731 Generation of a laser capture microdissection and RNAseq-based human anagen hair follicle transcriptome atlas. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
4
|
Scricciolo A, Lombardo V, Elli L, Bascuñán K, Doneda L, Rinaldi F, Pinto D, Araya M, Costantino A, Vecchi M, Roncoroni L. Use of a proline-specific endopeptidase to reintroduce gluten in patients with non-coeliac gluten sensitivity: A randomized trial. Clin Nutr 2022; 41:2025-2030. [DOI: 10.1016/j.clnu.2022.07.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 07/15/2022] [Accepted: 07/15/2022] [Indexed: 11/03/2022]
|
5
|
Pinto D, Calabrese F, m de angelis, Celano G, Giuliani G, Rinaldi F. 339 Lichen Planopilaris: The First Biopsy Layer Microbiota Inspection. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Pinto D, Giuliani G, Rinaldi F, Trink A. 291 In vitro efficacy of a sunscreen (50+) and octatrienoic acid 0.1% in actinic keratosis and UVs damages. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
7
|
Altieri M, Passi A, Vezzali R, Pinto D, Giuliani G, Rinaldi F. 374 Characterization of a class IIb gynecological medical device containing hyaluronic acid, beta-glucan, sericin and glycerophosphoinositol: mechanism of action and pilot clinical experience (case report). J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
8
|
Rinaldi F, Trink A, Sparavigna A, Pinto D. Photo-crosslinking of hyaluronic acid with low-level laser therapy device: a new combined and innovative approach. J BIOL REG HOMEOS AG 2021; 35:739-744. [PMID: 33988005 DOI: 10.23812/21-33-l] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - A Trink
- IHRF, International Hair Research Foundation, Milan, Italy
| | - A Sparavigna
- Derming, Clinical Research and Bioengineering Institute, Monza, Italy
| | | |
Collapse
|
9
|
Miscioscia A, Rinaldi F, Riguzzi P, Puthenparampil M, Gallo P. Encephalopathy as unique manifestation of Sjogren's syndrome: expanding the spectrum of steroid-responsive encephalopathy. Rheumatology (Oxford) 2021; 60:e174-e176. [PMID: 33399847 DOI: 10.1093/rheumatology/keaa813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2020] [Accepted: 11/01/2020] [Indexed: 11/14/2022] Open
Affiliation(s)
- A Miscioscia
- Neurology Unit, Department of Neuroscience, Università degli Studi di Padova
| | - F Rinaldi
- Neurology Unit, Azienda Ospedaliera di Padova, Padova, Italy
| | - P Riguzzi
- Neurology Unit, Department of Neuroscience, Università degli Studi di Padova
| | - M Puthenparampil
- Neurology Unit, Department of Neuroscience, Università degli Studi di Padova
| | - P Gallo
- Neurology Unit, Department of Neuroscience, Università degli Studi di Padova
| |
Collapse
|
10
|
Sforza S, Tuccio A, Zammarchi L, Verrienti P, Rinaldi F, Tilli M, Di Maida F, Mari A, Masieri L, Carini M, Bartoloni A, Minervini A. Urological management and surgical procedures in migrants from Sub-Saharan Africa with urogenital schistosomiasis. Actas Urol Esp 2021; 45:309-319. [PMID: 33685664 DOI: 10.1016/j.acuro.2020.03.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 03/12/2020] [Accepted: 03/22/2020] [Indexed: 11/29/2022]
Abstract
INTRODUCTION AND OBJECTIVES An increasing number of urogenital schistosomiasis (UGS) is being diagnosed in Europe following the unprecedented migratory flux from Sub-Saharan Africa (SSA). This phenomenon represent a challenge for urologists working in a non-endemic area. The aim of this study is to describe the urological management and the surgical procedures of patients with UGS in a tertiary referral centre. PATIENTS All subjects from SAA diagnosed with UGS from January 2011 to November 2018 were enrolled retrospectively. Detailed data of patients with UGS undergoing to urological procedures were collected and analysed. RESULTS Thirty patients were diagnosed with UGS, among them 12 (42.8%) were submitted to surgery. The most common surgical procedure was trans urethral resection of bladder (TURB) for suspected lesions persisted after praziquantel treatment performed in 7cases (58%). Other surgical procedure were TURB and concomitant ureteroscopy with laser fragmentation for suspected bladder neoplasm with renal stone, endoscopic lithotripsy and percutaneous nephrolithotomy for bladder and renal stones, laparoscopic nephrectomy for end-stage kidney disease, placement of bilateral nephrostomy for hydroureteronephrosis, explorative testicular surgery for a suspected testicular torsion in one case each. Four patients (33%) were lost at the follow up. CONCLUSION An increasing number of migrants from SSA diagnosed with UGS has been observed. Some patients required a surgical intervention for suspected neoplastic lesions or end-stage organ damage. It was particularly difficult to perform a regular follow-up in several patients. Further multicentric studies are needed to reach a proper standard in diagnosis, treatment and follow-up of subjects with UGS.
Collapse
Affiliation(s)
- S Sforza
- Department of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florencia, Italia
| | - A Tuccio
- Department of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florencia, Italia.
| | - L Zammarchi
- Infectious and Tropical Diseases Unit, Careggi Hospital, University of Florence, Florencia, Italia; Referral Centre for Tropical Diseases of Tuscany, Infectious and Tropical Diseases Unit, University of Florence, Florencia, Italia
| | - P Verrienti
- Department of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florencia, Italia
| | - F Rinaldi
- Infectious and Tropical Diseases Unit, Careggi Hospital, University of Florence, Florencia, Italia; Referral Centre for Tropical Diseases of Tuscany, Infectious and Tropical Diseases Unit, University of Florence, Florencia, Italia
| | - M Tilli
- Infectious and Tropical Diseases Unit, Careggi Hospital, University of Florence, Florencia, Italia; Referral Centre for Tropical Diseases of Tuscany, Infectious and Tropical Diseases Unit, University of Florence, Florencia, Italia
| | - F Di Maida
- Department of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florencia, Italia
| | - A Mari
- Department of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florencia, Italia
| | - L Masieri
- Department of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florencia, Italia
| | - M Carini
- Department of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florencia, Italia
| | - A Bartoloni
- Infectious and Tropical Diseases Unit, Careggi Hospital, University of Florence, Florencia, Italia; Referral Centre for Tropical Diseases of Tuscany, Infectious and Tropical Diseases Unit, University of Florence, Florencia, Italia
| | - A Minervini
- Department of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florencia, Italia
| |
Collapse
|
11
|
Lopez E, Jimenez F, Bertolini M, Alam M, Ward C, Cheret J, Westgate G, Rinaldi F, Paus R. 181 Topical Sandalore®, a specific OR2AT4-stimulating odorant, ameliorates telogen effluvium: Randomized, double-blinded, placebo-controlled trial. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
12
|
Bertolini M, Jimenez F, Lopez E, Alam M, Ward C, Chéret J, Westgate G, Rinaldi F, Paus R. 609 Topical Sandalore®, a specific OR2AT4-stimulating odorant, ameliorates female telogen effluvium: Randomized, double-blinded, placebo-controlled clinical trial. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
13
|
Corti M, Rinaldi F, Monti D, Ferrandi EE, Marrubini G, Temporini C, Tripodo G, Kupfer T, Conti P, Terreni M, Massolini G, Calleri E. Development of an integrated chromatographic system for ω-transaminase-IMER characterization useful for flow-chemistry applications. J Pharm Biomed Anal 2019; 169:260-268. [PMID: 30884324 DOI: 10.1016/j.jpba.2019.03.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 03/08/2019] [Accepted: 03/09/2019] [Indexed: 12/23/2022]
Abstract
An integrated chromatographic system was developed to rapidly investigate the biocatalytic properties of ω-transaminases useful for the synthesis of chiral amines. ATA-117, an (R)-selective ω-transaminase was selected as a proof of concept. The enzyme was purified and covalently immobilized on an epoxy monolithic silica support to create an immobilized enzyme reactor (IMER). Reactor efficiency was evaluated in the conversion of a model substrate. The IMER was coupled through a switching valve to an achiral analytical column for separation and quantitation of the transamination products. The best conditions of the transaminase-catalyzed bioconversion were optimized by a design of experiments (DoE) approach. The production of (R)-1-(4-methoxyphenyl)propan-2-amine and (R)-1-methyl-3-phenylpropylamine, intermediates for the synthesis of the bronchodilator formoterol and the antihypertensive dilevalol respectively, was achieved in the presence of different amino donors. The enantiomeric excess (ee) was determined off-line by developing a derivatization procedure using Nα-(2,4-dinitro-5-fluorophenyl)-L-alaninamide reagent. The most satisfactory conversion yields were 60% for (R)-1-(4-methoxyphenyl)propan-2-amine and 29% for (R)-1-methyl-3-phenylpropylamine, using isopropylamine as amino donor. The enantiomeric excess of the reactions were 84%R and 99%R, respectively.
Collapse
Affiliation(s)
- M Corti
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
| | - F Rinaldi
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
| | - D Monti
- Istituto di Chimica del Riconoscimento Molecolare, CNR, Via M. Bianco 9, 20131 Milan, Italy
| | - E E Ferrandi
- Istituto di Chimica del Riconoscimento Molecolare, CNR, Via M. Bianco 9, 20131 Milan, Italy
| | - G Marrubini
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
| | - C Temporini
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
| | - G Tripodo
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
| | - T Kupfer
- Merck KGaA, Frankfurter Straße 250, 64293 Darmstadt, Germany
| | - P Conti
- Department of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133 Milan, Italy
| | - M Terreni
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
| | - G Massolini
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
| | - E Calleri
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
| |
Collapse
|
14
|
Cristofari A, De Santis M, Lucidi S, Rinaldi F. Data and performance of an active-set truncated Newton method with non-monotone line search for bound-constrained optimization. Data Brief 2018; 21:2155-2169. [PMID: 30533467 PMCID: PMC6265501 DOI: 10.1016/j.dib.2018.11.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Accepted: 11/12/2018] [Indexed: 11/01/2022] Open
Abstract
In this data article, we report data and experiments related to the research article entitled "A Two-Stage Active-Set Algorithm for Bound-Constrained Optimization", by Cristofari et al. (2017). The method proposed in Cristofari et al. (2017), tackles optimization problems with bound constraints by properly combining an active-set estimate with a truncated Newton strategy. Here, we report the detailed numerical experience performed over a commonly used test set, namely CUTEst (Gould et al., 2015). First, the algorithm ASA-BCP proposed in Cristofari et al. (2017) is compared with the related method NMBC (De Santis et al., 2012). Then, a comparison with the renowned methods ALGENCAN (Birgin and Martínez et al., 2002) and LANCELOT B (Gould et al., 2003) is reported.
Collapse
Affiliation(s)
- A Cristofari
- Dipartimento di Matematica, Università di Padova, Via Trieste, 63, 35121 Padua, Italy
| | - M De Santis
- Dipartimento di Ingegneria Informatica, Automatica e Gestionale Sapienza Università di Roma, Via Ariosto, 25, 00185 Rome, Italy
| | - S Lucidi
- Dipartimento di Ingegneria Informatica, Automatica e Gestionale Sapienza Università di Roma, Via Ariosto, 25, 00185 Rome, Italy
| | - F Rinaldi
- Dipartimento di Matematica, Università di Padova, Via Trieste, 63, 35121 Padua, Italy
| |
Collapse
|
15
|
Rinaldi F, Seguella L, Gigli S, Hanieh PN, Del Favero E, Cantù L, Pesce M, Sarnelli G, Marianecci C, Esposito G, Carafa M. inPentasomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice. J Control Release 2018; 294:17-26. [PMID: 30529726 DOI: 10.1016/j.jconrel.2018.12.007] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Revised: 12/05/2018] [Accepted: 12/06/2018] [Indexed: 11/19/2022]
Abstract
Preclinical and clinical evidences have demonstrated that astroglial-derived S100B protein is a key element in neuroinflammation underlying the pathogenesis of Parkinson's disease (PD), so much as that S100B inhibitors have been proposed as promising candidates for PD targeted therapy. Pentamidine, an old-developed antiprotozoal drug, currently used for pneumocystis carinii is one of the most potent inhibitors of S100B activity, but despite this effect, is limited by its low capability to cross blood brain barrier (BBB). To overcome this problem, we developed a non-invasive intranasal delivery system, chitosan coated niosomes with entrapped pentamidine (inPentasomes), in the attempt to provide a novel pharmacological approach to ameliorate parkinsonism induced by subchronic MPTP administration in C57BL-6 J mice. inPentasomes, prepared by evaporation method was administered daily by intranasal route in subchronic MPTP-intoxicated rodents and resulted in a dose-dependent manner (0.001-0.004 mg/kg) capable for a significant Tyrosine Hydroxylase (TH) positive neuronal density rescue in both striatum and substantia nigra of parkinsonian mice. In parallel, inPentasomes significantly decreased the extent of glial-related neuroinflammation through the reduction of specific gliotic markers (Iba-1, GFAP, COX-2, iNOS) with consequent PGE2 and NO2- release reduction, in nigrostriatal system. inPentasomes-mediated S100B inhibition resulted in a RAGE/NF-κB pathway downstream inhibition in the nigrostriatal circuit, causing a marked amelioration of motor performances in intoxicated mice. On the basis of our results, chitosan coated niosomes loaded with pentamidine, the inPentasome system, self-candidates as a promising new intranasal approach to mitigate parkinsonism in humans and possibly paves the way for a possible clinical repositioning of pentamidine as anti-PD drug.
Collapse
Affiliation(s)
- F Rinaldi
- Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia (ITT), Rome, Italy
| | - L Seguella
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy
| | - S Gigli
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy
| | - P N Hanieh
- Department of Drug Chemistry and Technology, Sapienza University of Rome, Rome, Italy
| | - E Del Favero
- Department of Medical Biotechnologies and Translational Medicine, University of Milan, Italy
| | - L Cantù
- Department of Medical Biotechnologies and Translational Medicine, University of Milan, Italy
| | - M Pesce
- Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy
| | - G Sarnelli
- Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy
| | - C Marianecci
- Department of Drug Chemistry and Technology, Sapienza University of Rome, Rome, Italy.
| | - G Esposito
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy
| | - M Carafa
- Department of Drug Chemistry and Technology, Sapienza University of Rome, Rome, Italy
| |
Collapse
|
16
|
Flanigan K, Chicoine L, Cheatham J, Cheatham S, Simmons T, Lowes L, Iammarino M, Miller N, Alfano L, Rinaldi F, Waldrop M, Zygmunt D, Xu R, Martin P. DMD CLINICAL THERAPIES II. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
17
|
Abstract
SummaryFeldspars, paracelsian and danburite, harmotome and phillipsite have alumino-silicate frameworks that consist of three out of the seventeen simplest ways of cross-linking chains of the feldspar type. The four-membered rings that form the feldspar type of chain are parallel and have two adjacent tetrahedra pointing one way and the other two the other way. Chains are produced by sharing oxygen atoms of oppositely-pointing tetrahedra of parallel four-membered rings. Cross-linking of chains produces frameworks containing parallel eight-membered rings. If alternate tetrahedra in the rings point the same way, a new type of chain is produced, and there are four simple ways of joining these chains together to make a framework. If all four tetrahedra in a ring point the same way, only one structure can be developed, which has been proposed already by Barrer et al. for the zeolite Na-P1 and other members of the harmotome family. If three tetrahedra in the ring point the same way, very many simple structures can be constructed, and the seven simplest of these are described. It is suggested from comparison of cell dimensions that gismondine and, perhaps, yugawaralite may belong to this series of hypotheti- cal structures. It is also suggested that some of the complexity and confusion in the harmotome group of zeolites may arise from hitherto unrecognized members of this hypothetical group. Major angular distortions from the ideal shape occur for the naturally-occurring silicates belonging to these structural groups.
Collapse
|
18
|
Rinaldi F, Damioli S, Pasolini M, Maria GD, Padovani A, Filosto M. 55. Assessing the risk of restless legs syndrome in small fiber peripheral neuropathy. Clin Neurophysiol 2017. [DOI: 10.1016/j.clinph.2017.09.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Rinaldi F, Tengattini S, Calleri E, Bavaro T, Piubelli L, Pollegioni L, Massolini G, Temporini C. Application of a rapid HILIC-UV method for synthesis optimization and stability studies of immunogenic neo -glycoconjugates. J Pharm Biomed Anal 2017; 144:252-262. [DOI: 10.1016/j.jpba.2017.03.052] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Revised: 03/01/2017] [Accepted: 03/26/2017] [Indexed: 11/25/2022]
|
20
|
Anzola GP, Brighenti R, Cobelli M, Giossi A, Mazzucco S, Olivato S, Pari E, Piras MP, Padovani A, Rinaldi F, Turri G. Cerebral haemodynamics in early puerperium: A prospective study. Ultrasound 2017; 25:107-114. [PMID: 28567105 DOI: 10.1177/1742271x17690942] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Accepted: 01/08/2017] [Indexed: 11/15/2022]
Abstract
AIM Prospective study on 900 consecutive puerperae to assess normal values and range of the blood flow velocity in the middle cerebral artery in both hemispheres. MATERIAL AND METHOD M1 and M2 segments of both middle cerebral arteries were assessed in all subjects within 96 hours of delivery. Mean flow velocity was recorded after adjusting for insonation angle. Lindegaard index (LI = middle cerebral artery-Internal Carotid Artery mean flow velocity ratio) was calculated whenever the mean flow velocity exceeded 100 cm/second. Asymmetry indexes were calculated inter hemispherically for M1 and M2 segments separately. RESULTS Mean flow velocities were 74 ± 17 and 72 ± 17 in right and 73 ± 17 and 72 ± 17 cm/second in the left M1 and M2, respectively. A total of 136 subjects (12.1%) exceeded the threshold of 100 cm/second, but LI was consistently <3 in all of them. Mean flow velocity was inversely and independently correlated to haemoglobin levels and to parity. Mean asymmetry indexes were 0.25 ± 23 in M1 and 0.45 ± 25 in M2. CONCLUSION Mean flow velocity in the middle cerebral artery of healthy subjects in early puerperium is higher than in age-matched non-puerperal women and may exceed the threshold of 100 cm/second with no evidence of intracranial spasm, because of blood loss during delivery. Mean flow velocity is independently correlated with parity. Right-to-left mean flow velocity asymmetry may reach 50% as a consequence of a transient imbalance in vascular tone regulation.
Collapse
Affiliation(s)
- G P Anzola
- Consultant Neurologist, Villa Gemma Hospital, Gardone Riviera, Italy
| | - R Brighenti
- Department of Obstetrics and Gynaecology, Poliambulanza Hospital, Brescia, Italy
| | - M Cobelli
- Department of Radiology, Poliambulanza Hospital, Brescia, Italy
| | - A Giossi
- Department of Neurology, Azienda Socio Sanitaria Territoriale, Cremona, Italy
| | - S Mazzucco
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | | | - E Pari
- Deparment of Neurology, Spedali Civili, University of Brescia, Brescia, Italy
| | - M P Piras
- Deparment of Neurology, Poliambulanza Hospital, Brescia, Italy
| | - A Padovani
- Deparment of Neurology, Spedali Civili, University of Brescia, Brescia, Italy
| | - F Rinaldi
- Deparment of Neurology, Spedali Civili, University of Brescia, Brescia, Italy
| | - G Turri
- Department of Neurosciences, Biomedicine and Movement Sciences, University Hospital of Verona, Verona, Italy
| |
Collapse
|
21
|
Puthenparampil M, Federle L, Miante S, Zito A, Toffanin E, Ruggero S, Ermani M, Pravato S, Poggiali D, Perini P, Rinaldi F, Gallo P. BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset. J Neuroinflammation 2017; 14:11. [PMID: 28095856 PMCID: PMC5240243 DOI: 10.1186/s12974-016-0785-2] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2016] [Accepted: 12/28/2016] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND B lymphocytes are thought to play a relevant role in multiple sclerosis (MS) pathology. The in vivo analysis of intrathecally produced B cell-related cytokines may help to clarify the mechanisms of B cell recruitment and immunoglobulin production within the central nervous system (CNS) in MS. METHODS Paired cerebrospinal fluid (CSF) and serum specimens from 40 clinically isolated syndrome suggestive of MS or early-onset relapsing-remitting MS patients (CIS/eRRMS) and 17 healthy controls (HC) were analyzed for the intrathecal synthesis of IgG (quantitative formulae and IgG oligoclonal bands, IgGOB), CXCL13, BAFF, and IL-21. 3D-FLAIR, 3D-DIR, and 3D-T1 MRI sequences were applied to evaluate white matter (WM) and gray matter (GM) lesions and global cortical thickness (gCTh). RESULTS Compared to HC, CIS/eRRMS having IgGOB (IgGOB+, 26 patients) had higher intrathecal IgG indexes (p < 0.01), lower values of BAFF Index (11.9 ± 6.1 vs 17.5 ± 5.2, p < 0.01), and higher CSF CXCL13 levels (27.7 ± 33.5 vs 0.9 ± 1.5, p < 0.005). In these patients, BAFF Index but not CSF CXCL13 levels inversely correlated with the intrathecal IgG synthesis (r > 0.5 and p < 0.05 for all correlations). CSF leukocyte counts were significantly higher in IgGOB+ compared to IgGOB- (p < 0.05) and HC (p < 0.01), and correlated to CSF CXCL13 concentrations (r 0.77, p < 0.001). The gCTh was significantly lower in patients with higher CSF CXCL13 levels (2.41 ± 0.1 vs 2.49 ± 0.1 mm, p < 0.05), while no difference in MRI parameters of WM and GM pathology was observed between IgGOB+ and IgGOB-. CONCLUSIONS The intrathecal IgG synthesis inversely correlated with BAFF Index and showed no correlation with CSF CXCL13. These findings seem to indicate that intrathecally synthesized IgG are produced by long-term PCs that have entered the CNS from the peripheral blood, rather than produced by PCs developed in the meningeal follicle-like structures (FLS). In this study, CXCL13 identifies a subgroup of MS patients characterized by higher leukocyte counts in the CSF and early evidence of cortical thinning, further suggesting a role for this chemokine as a possible marker of disease severity.
Collapse
Affiliation(s)
- M. Puthenparampil
- Multiple Sclerosis Centre, Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| | - L. Federle
- Multiple Sclerosis Centre, Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| | - S. Miante
- Multiple Sclerosis Centre, Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| | - A. Zito
- Multiple Sclerosis Centre, Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| | - E. Toffanin
- Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| | - S. Ruggero
- Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| | - M. Ermani
- Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| | - S. Pravato
- Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| | - D. Poggiali
- Multiple Sclerosis Centre, Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| | - P. Perini
- Multiple Sclerosis Centre, Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| | - F. Rinaldi
- Multiple Sclerosis Centre, Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| | - P. Gallo
- Multiple Sclerosis Centre, Department of Neurosciences DNS, University Hospital–Medical School, via Giustiniani 5, 3518 Padova, Italy
| |
Collapse
|
22
|
Pinto D, Benedusi A, Rinaldi F, Marzani B. 134 In vitro biological activities of a cream designed for sensitive skin treatment. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Puthenparampil M, Miante S, Federle L, Zanetta C, Toffanin E, Ruggero S, Rinaldi F, Gallo P. BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset. J Neuroimmunol 2016; 297:63-7. [DOI: 10.1016/j.jneuroim.2016.05.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2016] [Revised: 05/06/2016] [Accepted: 05/11/2016] [Indexed: 12/24/2022]
|
24
|
Vena G, Cassano N, Alessandrini G, Fai D, Gabellone M, Ligori P, Malvindi C, Mancino A, Pellè S, Rinaldi F, Sodo M. Treatment of Mild to Moderate Plaque Psoriasis with Calcitriol Ointment Applied with or without a Dosing Device. EUR J INFLAMM 2016. [DOI: 10.1177/1721727x0700500205] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Results of topical treatments can be influenced by several factors, including accurate dosing based on the affected skin area. The aim of this open-labelled multicenter study is to evaluate if correct dosing of calcitriol ointment has an impact on the clinical response of plaque psoriasis. For this purpose, patients with plaque psoriasis eligible to be treated with calcitriol ointment were randomized to treatment with a ‘standardized dose’ method, using a dosing device (N. 100), or treatment without the device (N. 101), for 12 weeks. Regardless of the use of the dosing device, calcitriol ointment caused a significant reduction of both the severity of signs and symptoms and the extent of body surface area affected after both 4 weeks and 12 weeks. Clinical response was not significantly different between the two groups. Local adverse events occurred in 12 subjects (of whom five treated with the device) and were mild and transient in most cases.
Collapse
Affiliation(s)
| | | | | | - D. Fai
- Collegio Salentino di Dermatologia, Lecce, Italy
| | - M. Gabellone
- Collegio Salentino di Dermatologia, Lecce, Italy
| | - P. Ligori
- Collegio Salentino di Dermatologia, Lecce, Italy
| | - C. Malvindi
- Collegio Salentino di Dermatologia, Lecce, Italy
| | - A. Mancino
- Collegio Salentino di Dermatologia, Lecce, Italy
| | - S. Pellè
- Collegio Salentino di Dermatologia, Lecce, Italy
| | - F. Rinaldi
- Collegio Salentino di Dermatologia, Lecce, Italy
| | - M.R. Sodo
- Collegio Salentino di Dermatologia, Lecce, Italy
| |
Collapse
|
25
|
Ferini-Strambi L, Marelli S, Galbiati A, Rinaldi F, Giora E. REM Sleep Behavior Disorder (RBD) as a marker of neurodegenerative disorders. Arch Ital Biol 2015; 152:129-46. [PMID: 25828685 DOI: 10.12871/000298292014238] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Rapid eye movement (REM) sleep behavior disorder (RBD) can occur in the absence of any other obvious associated neurologic disorder or in association with a neurodegenerative disease, in which case it is considered as symptomatic RBD. RBD is frequently associated with Parkinson's disease (PD), Lewy body dementia or multiple system atrophy (MSA), and in several cases may even antedate the occurrence of motor symptoms by decades. When no neurologic disorder is obvious, RBD can be considered as idiopathic (iRBD). Several studies have looked at neurophysiologic and neuropsychological functions in iRBD and have found evidence of CNS dysfunction during both wakefulness and sleep in a variable proportion of these patients, challenging the concept of iRBD. Identifying subjects with a high risk of developing a neurodegenerative process may be crucial in order to develop early intervention strategies. Some prospective results in iRBD showed that potential markers of neurodegeneration are the following: 1) marked EEG slowing on spectral analysis; 2) decreased striatal 123I-FPCIT; 3) impaired color vision.
Collapse
Affiliation(s)
- L Ferini-Strambi
- Sleep Disorders Center, Division of Neuroscience, Università Vita-Salute San Raffaele, Milan, Italy.
| | - S Marelli
- Sleep Disorders Center, Division of Neuroscience, Università Vita-Salute San Raffaele, Milan, Italy.
| | - A Galbiati
- Sleep Disorders Center, Division of Neuroscience, Università Vita-Salute San Raffaele, Milan, Italy.
| | - F Rinaldi
- Sleep Disorders Center, Division of Neuroscience, Università Vita-Salute San Raffaele, Milan, Italy.
| | - E Giora
- Sleep Disorders Center, Division of Neuroscience, Università Vita-Salute San Raffaele, Milan, Italy.
| |
Collapse
|
26
|
Tamarozzi F, Rossi P, Galati F, Mariconti M, Nicoletti GJ, Rinaldi F, Casulli A, Pozio E, Brunetti E. The Italian registry of cystic echinococcosis (RIEC): the first prospective registry with a European future. Euro Surveill 2015; 20. [DOI: 10.2807/1560-7917.es2015.20.18.21115] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Cystic echinococcosis (CE), a worldwide zoonosis, is highly endemic in southern and eastern Europe. Its actual prevalence is unknown due to the lack of efficient reporting systems designed to take into account the particular features of the disease. Neglect of CE makes diagnosis and clinical management difficult outside referral centres, with inconsistencies in clinical practice and often unnecessary procedures carried out that have associated risks and costs. The Italian registry of CE (RIEC) is a prospective multicentre registry of CE patients seen from January 2012 in Italian health centres; data are voluntarily submitted to the registry. Its aims are to show the prevalence of CE in Italy, bring the importance of this infection to the attention of health authorities, encourage public health policies towards its control, and stimulate biological, epidemiological and clinical research on CE. From January 2012 to February 2014, a total 346 patients were enrolled in 11 centres, outnumbering national reports of many CE-endemic European countries. We discuss preliminary data and challenges of the RIEC, template for the European registry of CE, which has been implemented within the Seventh Framework Programme project HERACLES (Human cystic Echinococcosis ReseArch in CentraL and Eastern Societies) since September 2014.
Collapse
Affiliation(s)
- F Tamarozzi
- Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, WHO Collaborating Centre for Clinical Management of Cystic Echinococcosis, Pavia, Italy
| | - P Rossi
- Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - F Galati
- SIDBAE, Information Technology, Istituto Superiore di Sanità, Rome, Italy
| | - M Mariconti
- Division of Infectious and Tropical Diseases, San Matteo Hospital Foundation, University of Pavia, WHO Collaborating Centre for Clinical Management of Cystic Echinococcosis, Pavia, Italy
| | - G J Nicoletti
- Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, WHO Collaborating Centre for Clinical Management of Cystic Echinococcosis, Pavia, Italy
| | - F Rinaldi
- Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, WHO Collaborating Centre for Clinical Management of Cystic Echinococcosis, Pavia, Italy
| | - A Casulli
- Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - E Pozio
- Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - E Brunetti
- Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, WHO Collaborating Centre for Clinical Management of Cystic Echinococcosis, Pavia, Italy
- Division of Infectious and Tropical Diseases, San Matteo Hospital Foundation, University of Pavia, WHO Collaborating Centre for Clinical Management of Cystic Echinococcosis, Pavia, Italy
| |
Collapse
|
27
|
Passeri D, Rinaldi F, Ingallina C, Carafa M, Rossi M, Terranova ML, Marianecci C. Biomedical Applications of Nanodiamonds: An Overview. J Nanosci Nanotechnol 2015; 15:972-988. [PMID: 26353603 DOI: 10.1166/jnn.2015.9734] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Nanodiamonds are a novel class of nanomaterials which have raised much attention for application in biomedical field, as they combine the possibility of being produced on large scale using relatively inexpensive synthetic processes, of being fluorescent as a consequence of the presence of nitrogen vacancies, of having their surfaces functionalized, and of having good biocompatibility. Among other applications, we mainly focus on drug delivery, including cell interaction, targeting, cancer therapy, gene and protein delivery. In addition, nanodiamonds for bone and dental implants and for antibacterial use is discussed. Techniques for detection and imaging of nanodiamonds in biological tissues are also reviewed, including electron microscopy, fluorescence microscopy, Raman mapping, atomic force microscopy, thermal imaging, magnetic resonance imaging, and positron emission tomography, either in vitro, in vivo, or ex vivo. Toxicological aspects related to the use of nanodiamonds are also discussed. Finally, patents, preclinical and clinical trials based on the use of nanodiamonds for biomedical applications are reviewed.
Collapse
|
28
|
Coviello T, Trotta AM, Marianecci C, Carafa M, Di Marzio L, Rinaldi F, Di Meo C, Alhaique F, Matricardi P. Gel-embedded niosomes: preparation, characterization and release studies of a new system for topical drug delivery. Colloids Surf B Biointerfaces 2014; 125:291-9. [PMID: 25524220 DOI: 10.1016/j.colsurfb.2014.10.060] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2014] [Revised: 08/10/2014] [Accepted: 10/19/2014] [Indexed: 10/24/2022]
Abstract
In the present paper physical gels, prepared with two polysaccharides, Xanthan and Locust Bean Gum, and loaded with non-ionic surfactant vesicles, are described. The vesicles, composed by Tween20 and cholesterol or by Tween85 and Span20, were loaded with Monoammonium glycyrrhizinate for release experiments. Size and zeta (ζ)-potential of the vesicles were evaluated and the new systems were characterized by rheological and dynamo-mechanical measurements. For an appropriate comparison, a Carbopol gel and a commercial gel for topical applications were also tested. The new formulations showed mechanical properties comparable with those of the commercial product indicating their suitability for topical applications. In vitro release experiments showed that the polysaccharide network protects the integrity of the vesicles and leads to their slow release without disruption of the aggregated structures. Furthermore, being the vesicles composed of molecules possessing enhancing properties, the permeation of the loaded drugs topically delivered can be improved. Thus, the new systems combine the advantages of matrices for a modified release (polymeric component) and those of an easier permeability across the skin (vesicle components). Finally, shelf live experiments indicated that the tested gel/vesicle formulations were stable over 1 year with no need of preservatives.
Collapse
Affiliation(s)
- T Coviello
- Department of Drug Chemistry and Technologies, "Sapienza", University of Rome, Rome, Italy
| | - A M Trotta
- Department of Drug Chemistry and Technologies, "Sapienza", University of Rome, Rome, Italy
| | - C Marianecci
- Department of Drug Chemistry and Technologies, "Sapienza", University of Rome, Rome, Italy
| | - M Carafa
- Department of Drug Chemistry and Technologies, "Sapienza", University of Rome, Rome, Italy.
| | - L Di Marzio
- Department of Pharmacy, University of Chieti "G. D'Annunzio", Chieti, Italy
| | - F Rinaldi
- Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, Viale Regina Elena 291, 00185 Rome, Italy
| | - C Di Meo
- Department of Drug Chemistry and Technologies, "Sapienza", University of Rome, Rome, Italy
| | - F Alhaique
- Department of Drug Chemistry and Technologies, "Sapienza", University of Rome, Rome, Italy
| | - P Matricardi
- Department of Drug Chemistry and Technologies, "Sapienza", University of Rome, Rome, Italy
| |
Collapse
|
29
|
Filosto M, Cotelli M, Vielmi V, Todeschini A, Rinaldi F, Rota S, Scarpelli M, Padovani A. Late-Onset Glycogen Storage Disease Type 2. Curr Mol Med 2014; 14:971-978. [DOI: 10.2174/1566524014666141010131649] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2013] [Revised: 03/21/2014] [Accepted: 07/25/2014] [Indexed: 11/22/2022]
|
30
|
Rinaldi F, Hartfield EM, Crompton LA, Badger JL, Glover CP, Kelly CM, Rosser AE, Uney JB, Caldwell MA. Cross-regulation of Connexin43 and β-catenin influences differentiation of human neural progenitor cells. Cell Death Dis 2014; 5:e1017. [PMID: 24457961 PMCID: PMC4040652 DOI: 10.1038/cddis.2013.546] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2013] [Revised: 10/30/2013] [Accepted: 11/04/2013] [Indexed: 12/03/2022]
Abstract
Connexin43 (Cx43) is the most widely and abundantly expressed gap junction (GJ) protein and it is strongly associated with the regulation of cell cycle progression. Emerging roles for Cx43 in cell adhesion and migration during neural differentiation have also been recently recognized, and this has emphasized the involvement of Cx43 in different physiological process beyond its role as a GJ protein. In this study, we explore the function of Cx43 in the differentiation of human neural progenitor cells (hNPCs) using viral vectors that mediate the overexpression or knockdown of the protein. Results showed that in the absence of this protein fetal cortex-derived hNPCs differentiated toward a neuronal phenotype at expenses of a glial phenotype. Furthermore, the silencing of Cx43 did not affect hNPC proliferation rate or numbers of apoptotic cells. The increase in the number of neurons was not recapitulated when GJ intercellular communications were pharmacologically blocked, and this suggested that Cx43 was influencing hNPCs differentiation with a GJ-independent effect. In addition, Cx43 knockdown significantly increased β-catenin signaling, which has been shown to regulate the transcription of pro-neuronal genes during embryonic neural development. Our results add further support to the hypothesis that Cx43 protein itself regulates key signaling pathways during development and neurogenesis beyond its role as GJ protein.
Collapse
Affiliation(s)
- F Rinaldi
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - E M Hartfield
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - L A Crompton
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - J L Badger
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - C P Glover
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - C M Kelly
- Brain Repair Group, School of Biosciences, Life Science Building, University of Cardiff, Cardiff, UK
| | - A E Rosser
- Brain Repair Group, School of Biosciences, Life Science Building, University of Cardiff, Cardiff, UK
- Department of Neurology, School of Medicine, University of Cardiff, Cardiff, UK
| | - J B Uney
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| | - M A Caldwell
- Stem Cells and Neuroregeneration Research Group, School of Clinical Sciences, Medical Sciences Building, University Walk, University of Bristol, Bristol, UK
| |
Collapse
|
31
|
|
32
|
Puthenparampil M, Seppi D, Rinaldi F, Federle L, Calabrese M, Perini P, Gallo P. Increased incidence of multiple sclerosis in the Veneto region, Italy. Mult Scler 2013; 19:601-4. [PMID: 23599184 DOI: 10.1177/1352458512461970] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND To what extent the progressive increase in the incidence of multiple sclerosis (MS) observed in the province of Padova over the period 1970-1999 was an expression of a real increased risk of developing MS remained unclear. OBJECTIVE The objective of this paper is to update the epidemiological figures of MS and probe whether the risk of having MS has increased in the province of Padova during the decade 2000-2009. METHODS All patients born in Italy and having a diagnosis of MS or possible MS identified through analysis of all available sources of information were included in the study. The incidence and prevalence rates between 2000 and 2009 were obtained and compared with our previously published data. RESULTS On 31 December 2009, the overall prevalence was 139.5/100,000, 192.0 ± 9.5 for females and 83.9 ± 6.3 for males. During the decade 2000-2009, the overall incidence rate of MS was 5.5 ± 0.5, 7.4 ± 0.8 for females and 3.5 ± 0.6 for males. The onset-diagnosis delay, the female/male ratio and the mean age at onset did not significantly change compared to the prior period of observation. CONCLUSION Our findings support the hypothesis of a real increased risk of developing MS in the province of Padova. Moreover, the actual prevalence of 1.4/1000 makes our region a high-risk geographical area for MS. The role played by exogenous factors in determining susceptibility to MS needs to be thoroughly investigated.
Collapse
Affiliation(s)
- M Puthenparampil
- The Multiple Sclerosis Centre of the Veneto Region, First Neurology Clinic, Department of Neurosciences, University Hospital of Padova, Italy
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Rinaldi F, Gargioli A, Quagliotti F. PID and LQ Regulation of a Multirotor Attitude: Mathematical Modelling, Simulations and Experimental Results. J INTELL ROBOT SYST 2013. [DOI: 10.1007/s10846-013-9911-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, Rinaldi F. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol 2013; 169:690-4. [DOI: 10.1111/bjd.12397] [Citation(s) in RCA: 177] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/16/2013] [Indexed: 11/29/2022]
Affiliation(s)
- A. Trink
- International Hair Research Foundation (IHRF); Milan; Italy
| | - E. Sorbellini
- International Hair Research Foundation (IHRF); Milan; Italy
| | - P. Bezzola
- International Hair Research Foundation (IHRF); Milan; Italy
| | | | | | - Y. Ramot
- Department of Dermatology; Hadassah - Hebrew University Medical Center; Jerusalem; Israel
| | - F. Rinaldi
- International Hair Research Foundation (IHRF); Milan; Italy
| |
Collapse
|
35
|
Ghezzi A, Pozzilli C, Grimaldi LME, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler 2013; 19:1106-12. [PMID: 23401129 DOI: 10.1177/1352458512471878] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Limited information is available on the use of natalizumab (NA) in pediatric multiple sclerosis (ped-MS) patients. OBJECTIVE The purpose of this study was to describe the long-term effects of NA in a large cohort of active ped-MS patients. METHODS Patients with definite ped-MS were treated with NA if in the previous year they had experienced at least two relapses or a severe relapse with incomplete recovery while on immunomodulating treatment, or at least two relapses and new magnetic resonance imaging (MRI) lesions regardless of any prior treatment. RESULTS The study included 55 patients (mean age: 14.4 years, mean number of relapses: 4.4, pre-treatment mean disease duration: 25.5 months). They received a median number of 26 infusions. Three relapses occurred during the follow-up, one female patient continued to deteriorate in cognitive functioning. Mean Expanded Disability Status Scale (EDSS) scores decreased from 2.7 to 1.9 at the last visit (p<0.001). During the follow-up the majority of patients remained free from MRI activity. Transient and mild clinical adverse events occurred in 20 patients. Mild hematological abnormalities occurred in seven patients. Anti-JCV antibodies were detected in 20/51 tested patients. CONCLUSIONS NA was well tolerated in all patients. A strong suppression of disease activity was observed in the majority of patients during the follow-up.
Collapse
Affiliation(s)
- A Ghezzi
- Multiple Sclerosis Study Center, Hospital of Gallarate, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
|
37
|
Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P. Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012; 18:1640-3. [DOI: 10.1177/1352458512464282] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Clinical and/or neuroimaging evidence of disease reactivation has been described in multiple sclerosis (MS) patients after a break from natalizumab. Whether fingolimod might be a therapeutic option following natalizumab needs to be evaluated. Twenty-two relapsing remitting MS patients having JC virus antibodies (JCVAb+) in serum were shifted from natalizumab to fingolimod after a three-month washout period. Neurological evaluation with the Expanded Disability Status Scale (EDSS) was performed monthly for a mean follow-up period of nine months. In 20/22 patients, brain magnetic resonance imaging (MRI) was obtained within one month after therapy initiation. Disease reactivation was observed in 11/22 (50%) patients: clinical relapses in six patients (four patients within the first month of therapy) and MRI activity in a further five patients (three patients within the first month of therapy). Clinical and/or MRI signs suggestive of disease rebound were observed in three patients. Our data indicate that fingolimod does not exert clinical activity quickly enough to stop MS reactivation after a break from natalizumab.
Collapse
Affiliation(s)
- F Rinaldi
- Multiple Sclerosis Centre of Padova, University Hospital, Italy
| | - D Seppi
- Multiple Sclerosis Centre of Padova, University Hospital, Italy
| | - M Calabrese
- Multiple Sclerosis Centre of Padova, University Hospital, Italy
| | - P Perini
- Multiple Sclerosis Centre of Padova, University Hospital, Italy
| | - P Gallo
- Multiple Sclerosis Centre of Padova, University Hospital, Italy
| |
Collapse
|
38
|
Calabrese M, Poretto V, Favaretto A, Alessio S, Bernardi V, Romualdi C, Rinaldi F, Perini P, Gallo P. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 2012; 135:2952-61. [DOI: 10.1093/brain/aws246] [Citation(s) in RCA: 206] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
|
39
|
|
40
|
Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol 2012; 7:665-72. [PMID: 22585413 DOI: 10.1007/s11481-012-9366-z] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2011] [Accepted: 04/03/2012] [Indexed: 12/01/2022]
Abstract
The risk of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab for multiple sclerosis (MS) is a serious concern. The presence of anti-JC virus antibodies is a risk factor for PML development, but 2.5 % of the patients result falsely-negative, while the prognostic relevance of testing JCV-DNA in biological fluids of treated patients is debated. Aim of this work was to evaluate the utility of testing JCV-DNA, together with anti-JCV antibodies, in biological samples of treated patients as a tool for PML risk stratification. 126 subjects from 5 MS Centers in Italy were included in the study. We performed a cross-sectional study in 63 patients testing JCV-DNA in blood, peripheral blood cells and urine. We longitudinally assessed the presence of JCV-DNA in a cohort of 33 subjects, one of which developed PML. We could test retrospectively serum samples from another PML case occurred during natalizumab therapy. Anti-JCV antibodies and urinary JCV-DNA were both tested in 73 patients. No changes in JCV-DNA status occurred during natalizumab treatment. The subject who developed PML in the longitudinal cohort had detectable JCV-DNA in urine at all time-points while serum or blood from both PML patients were always negative before the onset of disease and, in one case, after. Four subjects with JCV-DNA in urine and undetectable anti-JCV antibodies were retested for anti-JCV antibodies and three out of four resulted positive. In conclusion, testing JCV-DNA in urine is complementary to testing anti-JCV antibodies in identifying patients at risk of PML.
Collapse
Affiliation(s)
- A Laroni
- Department of Neuroscience, Ophthalmology and Genetics, University of Genova, Via De Toni 5, 16132, Genoa, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Mult Scler 2012; 18:1760-7. [PMID: 22570359 DOI: 10.1177/1352458512447704] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Since cortical pathology has been indicated to play a relevant role in the physical and cognitive disability of multiple sclerosis (MS) patients, this study aims to analyze the efficacy of natalizumab in slowing down its progression. METHODS A total of 120 relapsing-remitting MS patients completed a 2-year prospective study: 35 received natalizumab, 50 received interferon beta-1a or glatiramer acetate (immunomodulatory agents - IMA) and 35 remained untreated. Forty healthy subjects constituted the reference population. Clinical and magnetic resonance imaging (MRI) evaluations (including cortical lesions and atrophy) were performed at baseline and after 2 years. RESULTS Natalizumab significantly reduced accumulation of new cortical lesions (0.2±0.6,range 0-3) compared to immunomodulatory agents (1.3±1.1 togli spazio, range 1-6, p=0.001) and no treatment (2.9±1.5, range 1-8, p<0.001). The percentage of patients with new cortical lesions was also lower in natalizumab-treated patients (20%) compared to IMA-treated and untreated patients (68.0% and 74.2%; p<0.001 for both comparisons). Furthermore, the progression of cortical atrophy was significantly reduced by natalizumab (% change=1.7%) compared to IMA (3.7%, p=0.003) and no therapy (4.6%, p<0.001). Finally, a greater percentage (51.4%) of natalizumab-treated patients remained disease-free (no clinical or MRI evidence of disease activity or progression) compared to IMA-treated (18%, p=0.001) and untreated patients (5.7%, p<0.001). CONCLUSIONS Natalizumab treatment significantly decreases cortical lesion accumulation and cortical atrophy progression in severe relapsing-remitting MS. While supporting the inflammatory origin of cortical lesions, our results highlight the significant impact of natalizumab on cortical pathology.
Collapse
Affiliation(s)
- F Rinaldi
- The Multiple Sclerosis Centre of Veneto Region, Department of Neurology, University Hospital of Padova, Italy
| | | | | | | | | | | |
Collapse
|
42
|
Conforti R, Taglialatela G, Rinaldi F, Quaranta E, Cirillo M, Paolisso G, Cirillo S. Cervical Chordoma. Neuroradiol J 2012; 25:185-7. [DOI: 10.1177/197140091202500205] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2011] [Accepted: 02/08/2012] [Indexed: 11/16/2022] Open
Abstract
Chordomas are rare and aggressive tumors derived from notochordal remnants, usually arising in the axial skeleton. The most frequently reported anatomic distribution of chordoma is 50% sacral, 35% spheno-occipital and 15% spinal. We describe the case of an elderly lady presenting with progressive dysphagia, headache and neck pain. We found an expansile mass extending from C1 to C3. While running the diagnostic plan we considered a variety of lesions possibly involving the cervical spine. Biopsy revealed the mass was a chordoma.
Collapse
Affiliation(s)
- R. Conforti
- Department of Neuroscience, Neuroradiology, Second University of Naples; Naples, Italy
| | - G. Taglialatela
- Department of Neuroscience, Neuroradiology, Second University of Naples; Naples, Italy
| | - F. Rinaldi
- Department of Neuroscience, Neuroradiology, Second University of Naples; Naples, Italy
| | - E. Quaranta
- Department of Neuroscience, Neuroradiology, Second University of Naples; Naples, Italy
| | - M. Cirillo
- Department of Neuroscience, Neuroradiology, Second University of Naples; Naples, Italy
| | - G. Paolisso
- Department of Neuroscience, Neuroradiology, Second University of Naples; Naples, Italy
| | - S. Cirillo
- Department of Neuroscience, Neuroradiology, Second University of Naples; Naples, Italy
| |
Collapse
|
43
|
Calabrese M, Seppi D, Romualdi C, Rinaldi F, Alessio S, Perini P, Gallo P. Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population. AJNR Am J Neuroradiol 2012; 33:1507-11. [PMID: 22422186 DOI: 10.3174/ajnr.a3011] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
BACKGROUND AND PURPOSE GM pathology is considered a major determinant of disability in MS, but the comprehension of its origin and progression rate is limited by the uncertainty of dating the biologic disease onset. Thus, we planned a longitudinal study aimed at analyzing and comparing cortical pathology in pediatric and adult MS patients at clinical onset. MATERIALS AND METHODS Within 12 months from clinical onset, 35 patients with cMS and 57 with aMS were included in a longitudinal study. At T0, GMf and CL number and volume were analyzed. Percentages of Δ-GMf and number of new CLs were assessed every year for 3 years (T1-T3). Twenty-eight age- and sex-matched NCs constituted the reference population. RESULTS At T0, GMf did not differ between cMS and NC (P = .18), while it was lower in patients with aMS compared with both NCs (P < .001) and patients with cMS (P < .001). The number of patients with CLs, as well as CL number and volume, were higher in patients with aMS than in those with cMS (P < .001). At T3, Δ-GMf was higher in both patients with cMS (1.6% ± 0.5%; range 0.7%-3.4%; P < .001) and aMS (1.6% ± 0.6%; range 0.6%-3.4%; P < .001) compared with NCs (0.7% ± 0.2%; range 0.4%-1.1%), whereas no difference was observed between patients with cMS and aMS (P = .93). Δ-GMf significantly correlated with increased CL volume (cMS: r = 0.46; aMS: r = 0.48) and with the appearance of new CLs (cMS: r = 0.51; aMS: r = 0.49). CONCLUSIONS Our findings suggest that focal (CLs) and diffuse (atrophy) GM damage are strictly associated with the biologic onset of MS, and proceed linearly and partly independently of WM pathology.
Collapse
Affiliation(s)
- M Calabrese
- Multiple Sclerosis Centre of Veneto Region-First Neurology Clinic, Department of Neurosciences, University Hospital of Padua, Italy.
| | | | | | | | | | | | | |
Collapse
|
44
|
Arya SK, Krishnan S, McGrath K, Rinaldi F, Bhansali S. Palladium Nanoparticles Film Based Concentration Specific Hydrogen Sensor. ACTA ACUST UNITED AC 2012. [DOI: 10.1166/sl.2012.2315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
45
|
Rinaldi F, Terracciano C, Pisani V, Massa R, Loro E, Vergani L, Di Girolamo S, Angelini C, Gourdon G, Novelli G, Botta A. Aberrant splicing and expression of the non muscle myosin heavy-chain gene MYH14 in DM1 muscle tissues. Neurobiol Dis 2012; 45:264-71. [DOI: 10.1016/j.nbd.2011.08.010] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2011] [Revised: 07/25/2011] [Accepted: 08/03/2011] [Indexed: 10/17/2022] Open
|
46
|
Calabrese M, Grossi P, Favaretto A, Romualdi C, Atzori M, Rinaldi F, Perini P, Saladini M, Gallo P. Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study. J Neurol Neurosurg Psychiatry 2012; 83:49-54. [PMID: 21890577 DOI: 10.1136/jnnp-2011-300414] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
INTRODUCTION The cause of epilepsy in multiple sclerosis (MS) has not yet been elucidated. The relevance of cortical pathology (cortical lesions and thickness) in MS patients with and without epilepsy was evaluated in a longitudinal study. METHODS 32 relapsing-remitting MS patients with epilepsy (RRMS/E) and 60 matched RRMS patients without epilepsy were included in a 3 year longitudinal study. The following clinical and MR parameters were analysed: Expanded Disability Status Scale (EDSS), cognitive score (CS), cortical lesion (CL) number and volume, grey matter fraction (GMf), global cortical thickness (CTh), T2 white matter lesion volume (T2WMLV), new CLs and new WM lesions. RESULTS At baseline (T0), CLs were observed in 27/32 (84.4%) RRMS/E and in 26/60 (43.3%) RRMS (p<0.001) patients, and the RRMS/E group had a higher number (10.2 ± 8.9 vs 4.5 ± 2.4; p<0.001) and total volume (2.0 ± 1.3 vs 0.7 ± 0.8 cm(3); p<0.001) of CLs compared with the RRMS group. No significant difference in T2WMLV was observed. Global CTh was lower in RRMS/E (2.12 ± 0.19 vs 2.35 ± 0.14 mm; p<0.001), and this group also showed a decline in cognition (CS 10.9 ± 6.3 vs 6.2 ± 3.5; p<0.001). After 3 years (T1), the RRMS/E group had a higher accumulation of new CLs (3.4 ± 3.2 vs 1.2 ± 1.1; p<0.001) and faster reduction of GMf (p=0.022) while the two groups did not differ in the number of new WM and new Gad+ lesions. DISCUSSION RRMS/E had a more severe and rapidly evolving cortical pathology (CLs and atrophy) compared with RRMS without epilepsy. The RRMS/E group was also characterised by more pronounced cognitive decline, higher EDSS and higher prevalence of men.
Collapse
Affiliation(s)
- M Calabrese
- Multiple Sclerosis Centre, First Neurology Clinic, University of Padova, Via Giustiniani 5, Padova 35128, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Affiliation(s)
- D Rebholz-Schuhmann
- EMBL Outstation, European Bioinformatics Institute, Hinxton, Cambridge, CB10 1SD, UK
| | | | | | | | | |
Collapse
|
48
|
Baracchini C, Perini P, Causin F, Calabrese M, Rinaldi F, Gallo P. Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency. Neurology 2011; 77:844-50. [PMID: 21849656 DOI: 10.1212/wnl.0b013e31822c6208] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE Chronic cerebrospinal venous insufficiency (CCSVI) had been suggested to play a major pathogenetic role in multiple sclerosis (MS), but recent data on early stages of MS have not confirmed this theory. Nonetheless, CCSVI could represent a late phenomenon of MS or be associated with progression of disability. Thus, we studied CCSVI prevalence in primary progressive (PP) and secondary progressive (SP) MS, to clarify whether CCSVI characterizes the progressive forms of this disease. METHODS A total of 35 patients with SPMS, 25 patients with PPMS, and 60 age- and gender-matched normal controls (NC) were enrolled into a cross-sectional study. Extracranial and transcranial high-resolution venous echo color Doppler sonography (ECDS-TCDS) was performed in all patients and NC. Those patients having any abnormal ultrasound finding were asked to undergo selective venography (VGF). RESULTS Patients with PPMS (11 women, 14 men; mean age 47 ± 11 years) had a disease duration of 11 ± 7 years and Expanded Disability Status Scale (EDSS) score of 6.0 ± 0.5. Patients with SPMS (22 women, 13 men; mean age 45 ± 14.5 years) had a disease duration of 18 ± 14 years and EDSS score of 6.0 ± 0.8. TCDS was normal in all patients. ECDS showed one or more abnormal findings in 9/60 (15.0%) patients (7/35 [20.0%] SPMS, 2/25 [8.0%] PPMS) and in 14/60 (23.3%) NC (p not significant for all comparisons). CCSVI criteria were fulfilled in 0 NC and 4 (6.7%) patients with MS: 3 SPMS and 1 PPMS. VGF, performed in 6/9 patients, was abnormal only in one case who had bilateral internal jugular vein stenosis. CONCLUSION Our findings indicate that CCSVI is not a late secondary phenomenon of MS and is not associated with disability.
Collapse
Affiliation(s)
- C Baracchini
- First Neurology Clinic, Department of Neuroscience, University of Padua, Padova, Italy.
| | | | | | | | | | | |
Collapse
|
49
|
Calabrese M, Rinaldi F, Mattisi I, Bernardi V, Favaretto A, Perini P, Gallo P. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011; 77:257-63. [PMID: 21613600 DOI: 10.1212/wnl.0b013e318220abd4] [Citation(s) in RCA: 121] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Although gray matter (GM) atrophy is recognized as a common feature of multiple sclerosis (MS), conflicting results have been obtained in patients with clinically isolated syndromes (CIS). Methodologic and clinical constraints may take account for literature discrepancies. METHODS A total of 105 patients presenting with CIS and 42 normal controls (NC) were studied. At baseline, 65/105 patients with CIS met the criterion of dissemination in space of lesions (DIS+). All patients were clinically assessed by means of the Expanded Disability Status Scale every 6 months and underwent MRI evaluation at study entry and then annually for 4 years. Global and regional cortical thickness and deep GM atrophy were assessed using Freesurfer. RESULTS No significant reduction in GM atrophy was observed between the entire CIS group and the NC, excepting for the cerebellum cortical volume. When the 59 patients with CIS (46 DIS+, 13 DIS-) who converted to MS during the follow-up were compared to the NC, a significant atrophy in the precentral gyrus, superior frontal gyrus, thalamus, and putamen was observed (p ranging from 0.05 to 0.001). The multivariate analysis identified the atrophy of superior frontal gyrus, thalamus, and cerebellum as independent predictors of conversion to MS. CIS with atrophy of such areas had a double risk of conversion compared to DIS+ (odds ratio 9.6 vs 5.0). CONCLUSION Selective GM atrophy is relevant in patients with CIS who convert early to MS. The inclusion of GM analysis in the MS diagnostic workup is worthy of further investigation.
Collapse
Affiliation(s)
- M Calabrese
- Multiple Sclerosis Centre of Veneto Region, First Neurology Clinic, Department of Neurosciences, University Hospital of Padova, Via Giustiniani 5, 35128 Padova, Italy.
| | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system. In the last decade, pathological and magnetic resonance imaging (MRI) studies have shown that a significant portion of inflammatory lesions are located in the grey matter, especially in the cerebral cortex, of MS patients. Cortical inflammatory lesions (CL) can be demonstrated in vivo in MS patients by double inversion recovery (DIR) MRI sequence. Neuropsychological deficits constitute a major clinical aspect of MS, being demonstrated in a percentage ranging from 40 to 65% of patients, and have been shown to be associated with cortical demyelination and atrophy. Recent DIR studies in MS patients having different clinical forms of the disease have disclosed that CL burden not only correlates with the severity of physical disability, but is also one of the major structural changes associated with disease-related cognitive impairment.
Collapse
Affiliation(s)
- F Rinaldi
- Department of Neurosciences, The Multiple Sclerosis Centre of Veneto Region, University Hospital of Padova, Padua, Italy.
| | | | | | | | | | | |
Collapse
|